1. Home
  2. XPRO vs NRIX Comparison

XPRO vs NRIX Comparison

Compare XPRO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expro Group Holdings N.V.

XPRO

Expro Group Holdings N.V.

HOLD

Current Price

$14.62

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPRO
NRIX
Founded
1938
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
XPRO
NRIX
Price
$14.62
$18.81
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$14.00
$29.08
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
02-24-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
313.92
N/A
EPS
0.59
N/A
Revenue
$1,661,811,000.00
$83,687,000.00
Revenue This Year
N/A
$59.40
Revenue Next Year
$1.78
N/A
P/E Ratio
$23.66
N/A
Revenue Growth
N/A
48.32
52 Week Low
$6.70
$8.18
52 Week High
$15.04
$22.50

Technical Indicators

Market Signals
Indicator
XPRO
NRIX
Relative Strength Index (RSI) 59.75 56.96
Support Level $13.96 $16.98
Resistance Level $14.94 $19.54
Average True Range (ATR) 0.41 0.94
MACD 0.11 -0.28
Stochastic Oscillator 84.90 63.99

Price Performance

Historical Comparison
XPRO
NRIX

About XPRO Expro Group Holdings N.V.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: